Last reviewed · How we verify
NCT05054777
Patient Report Outcome and Oncological Safety -Oncoplastic and Conventional BCS Cohort
trial testing oncoplastic breast-conserving surgery in Patient Reported Outcome in 5,000 participants. Status unknown.
30 December 2024
Quick facts
| Lead sponsor | Shandong Cancer Hospital and Institute |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 5,000 |
| Start date | 1 October 2021 |
| Primary completion | 30 December 2024 |
| Estimated completion | 30 December 2024 |
Drugs / interventions tested
- oncoplastic breast-conserving surgery
- conventional breast-conserving surgery
Conditions studied
- Patient Reported Outcome — all drugs for Patient Reported Outcome →
- Oncological Safety — all drugs for Oncological Safety →
- Breast-conserving Surgery — all drugs for Breast-conserving Surgery →
- Breast Cancer Female — all drugs for Breast Cancer Female →
Sponsor
Shandong Cancer Hospital and Institute
Who can join
Adults 18 to 80, female only, with Patient Reported Outcome or Oncological Safety. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Breast-conserving surgery (BCS) is the traditional surgical treatment for early-stage breast cancer patients. There are evidences indicating that oncoplastic BCS could improve cosmetic outcomes and/or quality of life, and has similar oncological safety as conventional BCS does. However, these studies that focused on patient-reported outcomes and oncological safety were mainly from one institution or of small sample size. The variations across hospitals and regions were not fully analyzed. A multicenter prospective patient report outcome (PROs) and oncological safety will be planned to assess the PROs and safety for Chinese breast cancer patients who will undergo oncoplastic and conventional breast-conserving surgery (OBCS). This study follows the Helsinki Declaration and Chinese rules. All patients will be asked to sign the informed consent and will be followed up 24 months after operations. All data will be collected.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05054777
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of oncoplastic breast-conserving surgery
Trials testing the same drug.
- NCT04030845 — Patient Report Outcome-Reconstruction and Oncoplastic Cohort · unknown
Other Shandong Cancer Hospital and Institute trials
Trials by the same sponsor.
- NCT07408505 — Nano-Megestrol Acetate for Cancer Cachexia in Advanced Pancreatic Cancer · NA · recruiting
- NCT07403370 — Olanzapine Dose Comparison for the Prevention of HER-INV: A Network Meta-Analysis · recruiting
- NCT07376174 — The Prognostic Impact of HER2 Expression in Non-Metastatic HER2-Positive Breast Cancer Treated With Dual HER2-Targeted T · recruiting
- NCT07333274 — Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Adva · Phase 3 · recruiting
- NCT07274774 — SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05054777 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shandong Cancer Hospital and Institute
- Last refreshed: 23 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05054777.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing